Ildong Bioscience of Ildong Pharmaceutical Group Presents Research Achievements at Microbiome Expo

Three Research Posters on Probiotics Unveiled at '2025 Probiota Americas'

Ildong Bioscience, the health functional food business unit of Ildong Pharmaceutical Group, announced on June 17 that it participated in the 2025 Probiota Americas to promote its functional ingredients and explore new business opportunities.

Probiota Americas is an international expo focused on academic and industrial exchange in the microbiome sector. This year’s event was held in Vancouver, Canada, from June 9 to June 11. Marking its 10th anniversary, the event featured a variety of programs, including academic seminars, exhibition halls, and business networking sessions.

Ildong Pharmaceutical Group's Ildong Bioscience is participating in 2025 Probiota America, presenting research achievements on probiotics. Photo by Ildong Bioscience

Ildong Bioscience set up an exhibition booth at the venue to conduct promotional activities related to its business. During the event, the company presented its research findings on functional probiotics and postbiotics in the form of posters.

The topics presented by Ildong Bioscience included a total of three research studies: ▲Lacticaseibacillus rhamnosus IDCC 3201 (RH 3201), ▲Bifidobacterium lactis IDCC 4301, and ▲heat-treated culture powder of Bifidobacterium breve IDCC 4401 (BBR 4401).

First, in a human clinical trial investigating the improvement of constipation-predominant irritable bowel syndrome (IBS-C) using Lacticaseibacillus rhamnosus IDCC 3201 (RH 3201), the group that consumed RH 3201 for eight weeks showed significant alleviation of abdominal discomfort and bloating. Additionally, there was an observed increase in beneficial gut microbiota such as Bacteroides cellulosilyticus and Akkermansia muciniphila, as well as improvements in gut environment and function, evidenced by increased levels of intestinal metabolites including N-acetylornithine, xanthine, and 3-phenylpropionic acid.

In research utilizing the live probiotic Bifidobacterium lactis IDCC 4301, which suppresses body fat accumulation and activates energy metabolism, both animal studies and a 12-week human trial demonstrated significant reductions in body fat, abdominal fat, and blood triglyceride levels. The leptin/adiponectin ratio also improved, indicating the potential for restoring metabolic balance.

For Bifidobacterium breve IDCC 4401 heat-treated culture powder (BBR 4401), a postbiotic individually recognized for its functionality by the Ministry of Food and Drug Safety, studies in hyperlipidemic animal models and human trials showed efficacy in lowering LDL cholesterol and apolipoprotein B levels, inhibiting hepatic fat accumulation, and increasing bile acid excretion. In a 12-week human trial, BBR 4401 significantly reduced LDL-C levels without any notable adverse reactions.

A representative from Ildong Bioscience stated, "This was an opportunity to confirm our competitive edge in the microbiome field, including our differentiated strains, related technologies, and research and development capabilities." The representative added, "Based on these research achievements, we plan to expand the development of functional ingredients and products and accelerate our entry into both domestic and international markets."